CN210894377U - Novel coronavirus differential diagnosis test paper strip and detection card - Google Patents
Novel coronavirus differential diagnosis test paper strip and detection card Download PDFInfo
- Publication number
- CN210894377U CN210894377U CN202020169935.3U CN202020169935U CN210894377U CN 210894377 U CN210894377 U CN 210894377U CN 202020169935 U CN202020169935 U CN 202020169935U CN 210894377 U CN210894377 U CN 210894377U
- Authority
- CN
- China
- Prior art keywords
- detection line
- novel coronavirus
- influenza virus
- line
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The utility model discloses a novel coronavirus differential diagnosis test strip, which comprises a bottom plate with a strip-shaped structure, wherein a sample pad, a marker pad, a nitrocellulose membrane and absorbent paper are sequentially arranged on the upper surface of the bottom plate along the longitudinal direction of the bottom plate; and the adjacent ends of the sample pad, the marker pad, the nitrocellulose membrane and the absorbent paper are in lap joint; the marker pad is coated with a novel coronavirus monoclonal antibody or/and a polyclonal antibody and a rabbit IgG antibody which are respectively marked by markers; and a detection area is formed on one side of the upper surface of the nitrocellulose membrane, a novel coronavirus detection line is arranged in the detection area, and the novel coronavirus detection line is coated with a novel coronavirus monoclonal antibody or/and a polyclonal antibody. The utility model also discloses a novel coronavirus differential diagnosis detects card. The utility model has the characteristics of can short-term test novel coronavirus, influenza virus, pneumonia mycoplasma and pneumonia chlamydia, when can shortening the detection usefulness, realize on-the-spot short-term test.
Description
Technical Field
The utility model relates to a biomedical technical field especially relates to a novel coronavirus differential diagnosis test paper strip and detection card.
Background
The 2019 novel coronavirus, namely '2019-nCoV', is discovered due to 2019 novel coronavirus pneumonia cases, and is named by world health organization in 1 month and 12 days of 2020. Coronaviruses are a large family of viruses known to cause the common cold and more serious diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The novel coronavirus is a new strain of coronavirus that has not been previously discovered in humans.
The new type coronavirus belongs to the β genus new type coronavirus, which has envelope, round or elliptic particle, usually polymorphism, diameter of 60-140nm, and its gene characteristic has obvious difference with SARSr-CoV and MERSR-CoV, the present research shows that the homology with bat SARS-like coronavirus (bat-SL-CoVZC45) is up to more than 85%, when in vitro separation culture, 2019-nCoV can be found in human respiratory epithelial cell in about 96 hours, while in Vero E6 and Huh-7 cell line, the separation culture takes 6 days.
The pneumonia diagnosis and treatment scheme of the novel coronavirus infection clearly provides that the pneumonia infected by the novel coronavirus needs to be identified with other known viral pneumonia such as influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS coronavirus and the like, and also identified with mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia and the like.
Since the outbreak of pneumonia epidemic infected by a novel coronavirus (2019-nCoV), the rapid marketing and clinical application of a common real-time quantitative fluorescent PCR nucleic acid detection reagent play an important role in clinical diagnosis and investigation of suspected patients, but the detection requirements of investigation and diagnosis of a large number of suspected patients, asymptomatic infectors and the like which are rapidly increased at present cannot be met due to the limitations of complex operation, long time consumption, need of centralized inspection and the like.
The detection of the existing novel coronavirus (2019-nCoV) urgently needs a field rapid detection product, can break through the limitation of the existing detection technology on personnel/places, improves the convenience degree when the detection is shortened, promotes the forward movement and the downward movement of diagnosis, and realizes the rapid diagnosis of suspected patients and the field screening of close contact crowds.
SUMMERY OF THE UTILITY MODEL
To the not enough of above-mentioned prior art, the utility model aims to solve the technical problem that: how to provide a test paper strip and test card, make it can short-term test novel coronavirus (2019-nCoV), influenza virus, mycoplasma pneumoniae and chlamydia pneumoniae, promote convenient degree, promote the diagnosis to move forward when can shortening the measuring time, realize the quick diagnosis of suspected patient and the on-the-spot screening of close contact crowd better.
In order to solve the technical problem, the utility model discloses a following technical scheme:
a novel coronavirus differential diagnosis test strip is characterized by comprising a bottom plate with a strip-shaped structure, wherein a sample pad, a marker pad, a nitrocellulose membrane and absorbent paper are sequentially arranged on the upper surface of the bottom plate along the longitudinal direction of the bottom plate; and the adjacent ends of the sample pad, the marker pad, the nitrocellulose membrane and the absorbent paper are in lap joint; the marker pad is coated with a novel coronavirus monoclonal antibody or/and a polyclonal antibody and a rabbit IgG antibody which are respectively marked by markers; a detection area is formed on one side of the upper surface of the nitrocellulose membrane, a novel coronavirus detection line is arranged in the detection area, and the novel coronavirus detection line is coated with a novel coronavirus monoclonal antibody or/and a polyclonal antibody.
As optimization, a quality control area is formed on the other side of the upper surface of the nitrocellulose membrane; the quality control area is provided with a quality control line coated with goat anti-rabbit IgG antibody.
As optimization, the marker pad is further coated with influenza virus monoclonal antibody or/and polyclonal antibody marked by markers respectively, mycoplasma pneumoniae monoclonal antibody or/and polyclonal antibody marked by markers and chlamydia pneumoniae monoclonal antibody or/and polyclonal antibody marked by markers; the detection area is also provided with an influenza virus detection line, a mycoplasma pneumoniae detection line and a chlamydia pneumoniae detection line; the influenza virus detection line is coated with influenza virus monoclonal antibodies or/and polyclonal antibodies, the mycoplasma pneumoniae detection line is coated with mycoplasma pneumoniae monoclonal antibodies or/and polyclonal antibodies, and the chlamydia pneumoniae detection line is coated with chlamydia pneumoniae monoclonal antibodies or/and polyclonal antibodies.
As optimization, the novel coronavirus detection line is coated with a novel coronavirus monoclonal antibody, the influenza virus detection line is coated with an influenza virus monoclonal antibody, the mycoplasma pneumoniae detection line is coated with a mycoplasma pneumoniae monoclonal antibody, and the chlamydia pneumoniae detection line is coated with a chlamydia pneumoniae monoclonal antibody.
As optimization, the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are arranged in parallel and sequentially arranged from left to right.
As optimization, the intervals between the adjacent novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are arranged equally; the lengths of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are arranged in an equal way; the widths of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are arranged in an equal way.
As optimization, the interval between the adjacent two of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line is 1.0mm to 3.0 mm; the length of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line is 2.0mm to 5.0mm, and the width of the novel coronavirus detection line is 0.5mm to 1.0 mm.
Preferably, the length of the nitrocellulose membrane is 2cm to 3cm, and the width is 2.0mm to 5.0 mm.
Preferably, the sample pad is lapped on the marker pad, and the length of the lapping part is 1.0-3.0 mm; the marker pad is lapped on the nitrocellulose membrane, the length of a lapping part is 1.0-3.0 mm, the absorbent paper is lapped on the nitrocellulose membrane, and the lapping length is 1.0-3.0 mm.
The utility model also discloses a novel coronavirus differential diagnosis test card, which is characterized by comprising the novel coronavirus differential diagnosis test strip; still including the last card shell and the lower card shell of dismantling the connection, be fixed with on the card shell down the test paper strip, go up card shell correspondence has the position of sample pad is provided with the application of sample hole and corresponds the nitrocellulose membrane position is provided with the detection window.
In summary, when the test strip and the detection card are used, a sample to be detected is taken, the sample to be detected can be a human nose swab or a pharynx swab, then the human nose swab or the pharynx swab is added into a lysis solution for treatment, the lysis solution is added into a sample adding hole of the detection card, the detection card is placed still for 10-20 minutes at room temperature, and then the result of interpretation is visually observed, or the detection card is inserted into an immune quantitative analyzer for interpretation. Judging the specific result, and judging by naked eyes: and (3) the visual inspection quality control line is red, which indicates that the quality control is normal, the detection result is effective, then a visible red line appears on the visual inspection line, which indicates that the detection result is positive, and if no visible red line exists on the visual inspection line, which indicates that the detection result is negative. And (3) interpretation by an instrument: the test card with complete reaction is inserted into an immunoassay analyzer, and the test result of each item of the novel coronavirus (2019-nCoV)/influenza virus/mycoplasma pneumoniae/chlamydia pneumoniae is automatically interpreted by the analyzer and is shown as negative (-) or positive (+) ".
The detection test strip and the detection card can realize rapid field detection of novel coronavirus (2019-nCoV), influenza virus, mycoplasma pneumoniae and chlamydia pneumoniae, can break through the limitation of the existing detection technology on personnel/places, are short in detection time and simple to operate, can be used in places such as community health service centers, primary hospitals, airports, customs and families, and can realize rapid differential diagnosis of suspected patients of the novel coronavirus (2019-nCoV) and field screening of close contact people.
Drawings
Fig. 1 is a schematic structural diagram of a novel coronavirus differential diagnosis test strip in an embodiment of the present invention.
Fig. 2 is a schematic cross-sectional view of a novel coronavirus differential diagnosis test strip according to an embodiment of the present invention.
Fig. 3 is a schematic structural diagram of the novel coronavirus differential diagnosis detection card of the present invention.
Detailed Description
The invention will be further explained with reference to the following figures and examples:
referring to fig. 1 to 3: a novel coronavirus differential diagnosis test strip is characterized by comprising a bottom plate 1 with a strip-shaped structure, wherein a sample pad 2, a marker pad 3, a nitrocellulose membrane 4 and absorbent paper 5 are sequentially arranged on the upper surface of the bottom plate along the longitudinal direction of the bottom plate; and the adjacent ends of the sample pad, the marker pad, the nitrocellulose membrane and the absorbent paper are in lap joint; the marker pad is coated with a novel coronavirus monoclonal antibody or/and a polyclonal antibody and a rabbit IgG antibody which are respectively marked by colloidal gold; a detection area is formed on one side of the upper surface of the nitrocellulose membrane, a novel coronavirus detection line 6 is arranged in the detection area, and the novel coronavirus detection line is coated with a novel coronavirus monoclonal antibody or/and a polyclonal antibody.
Wherein, the colloidal gold is used as a marker.
In this embodiment, the other side of the upper surface of the nitrocellulose membrane forms a quality control region; the quality control area is provided with a quality control line 10 coated with goat anti-rabbit IgG antibody.
In this embodiment, the marker pad further comprises a monoclonal antibody and/or a polyclonal antibody of influenza virus respectively labeled with colloidal gold, a monoclonal antibody and/or a polyclonal antibody of mycoplasma pneumoniae labeled with colloidal gold, a monoclonal antibody and/or a polyclonal antibody of chlamydia pneumoniae labeled with colloidal gold, and a rabbit IgG antibody labeled with colloidal gold; the detection area is also provided with an influenza virus detection line 7, a mycoplasma pneumoniae detection line 8 and a chlamydia pneumoniae detection line 9; the influenza virus detection line is coated with influenza virus monoclonal antibodies or/and polyclonal antibodies, the mycoplasma pneumoniae detection line is coated with mycoplasma pneumoniae monoclonal antibodies or/and polyclonal antibodies, and the chlamydia pneumoniae detection line is coated with chlamydia pneumoniae monoclonal antibodies or/and polyclonal antibodies.
In this embodiment, the novel coronavirus detection line is coated with a novel coronavirus monoclonal antibody, the influenza virus detection line is coated with an influenza virus monoclonal antibody, the mycoplasma pneumoniae detection line is coated with a mycoplasma pneumoniae monoclonal antibody, and the chlamydia pneumoniae detection line is coated with a chlamydia pneumoniae monoclonal antibody.
In this embodiment, the novel coronavirus detection line 6, the influenza virus detection line 7, the mycoplasma pneumoniae detection line 8, the chlamydia pneumoniae detection line 9, and the quality control line 10 are parallel to each other and are sequentially arranged from left to right.
In the specific embodiment, the intervals between the adjacent two of the novel coronavirus detection line 6, the influenza virus detection line 7, the mycoplasma pneumoniae detection line 8, the chlamydia pneumoniae detection line 9 and the quality control line 10 are equal; the lengths of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are arranged in an equal way; the widths of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are arranged in an equal way.
In the specific embodiment, the interval between the adjacent two of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line is 1.0mm to 3.0 mm; the length of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line is 2.0mm to 5.0mm, and the width of the novel coronavirus detection line is 0.5mm to 1.0 mm.
Specifically, the interval between the detection lines may be, but not limited to, 1.0mm, 2.0mm or 3.0mm, the length of the quality control line and each detection line may be, but not limited to, 2.0mm, 3.0mm, 4.0mm or 5.0mm, and the width of the quality control line and each detection line may be, but not limited to, 0.5mm, 0.6mm, 0.7mm, 0.8mm, 0.9mm or 1.0 mm.
In this embodiment, the nitrocellulose membrane has a length of 2cm to 3cm and a width of 2.0mm to 5.0 mm.
Specifically, the length of the nitrocellulose membrane is 2.0cm, 2.5cm or 3.0cm, and the width of the nitrocellulose membrane is 2.0mm, 3.0mm, 4.0mm or 5.0 mm.
In this embodiment, the sample pad is lapped on the marker pad, and the length of the lapping part is 1.0 to 3.0 mm; the marker pad is lapped on the nitrocellulose membrane, the length of a lapping part is 1.0-3.0 mm, the absorbent paper is lapped on the nitrocellulose membrane, and the lapping length is 1.0-3.0 mm.
In practice, the sample pad is 15mm to 30mm in length and 2mm to 5mm in width. More specifically, the sample pad has a length of 17mm to 24mm and a width of 3.8mm to 4.2 mm. More specifically, the sample pad length may be, but is not limited to, 17mm, 18mm, 20mm, 22mm,24 mm. More specifically, the sample pad has a length of 23 mm.
In practice, the marker pad is 4.0mm to 30.0mm in length and 2mm to 5mm in width. Specifically, the marker pad has a length of 8mm to 12mm and a width of 3.8mm to 4.2 mm. More specifically, the marker pad length may be, but is not limited to, 8mm, 9mm, 10mm, 11 mm. More specifically, the length of the sample pad is 10 mm.
In practice, the absorbent paper has a length of 15mm to 30mm and a width of 2mm to 5 mm. Specifically, the length of the absorbent paper is 17mm to 25mm, and the width of the absorbent paper is 3.8mm to 4.2 mm. Specifically, the length may be, but is not limited to, 17mm, 20mm, 23mm, 25 mm. More specifically, the length of the sample pad is 23 mm.
In practice, the sample pad 2, the marker pad 3, the nitrocellulose membrane (NC membrane) 4 and the absorbent paper 5 are equal in width.
A novel coronavirus differential diagnosis test card is characterized by comprising the novel coronavirus differential diagnosis test strip; still including last card shell and the lower card shell of dismantling the connection, be fixed with on the card shell down the test paper strip, it has to go up the correspondence of card shell the position of sample pad is provided with application of sample hole 11 and corresponds the nitrocellulose membrane position is provided with detection window 12.
In summary, when the test strip and the test card are used, a sample to be detected is taken, the sample to be detected can be a human nose swab or a pharynx swab, then the human nose swab or the pharynx swab is added into a lysis solution for treatment, the lysis solution is added into a sample adding hole of the test card or a nitrocellulose membrane of the test strip, the test card or the test strip is kept stand for 10-20 minutes at room temperature, and then the result is visually read, or the test card or the test strip is inserted into an immune quantitative analyzer for reading. Judging the specific result, and judging by naked eyes: and (3) the visual inspection quality control line is red, which indicates that the quality control is normal, the detection result is effective, then a visible red line appears on the visual inspection line, which indicates that the detection result is positive, and if no visible red line exists on the visual inspection line, which indicates that the detection result is negative. And (3) interpretation by an instrument: the test card with complete reaction is inserted into an immunoassay analyzer, and the test result of each item of the novel coronavirus (2019-nCoV)/influenza virus/mycoplasma pneumoniae/chlamydia pneumoniae is automatically interpreted by the analyzer and is shown as negative (-) or positive (+) ".
The detection test strip and the detection card can realize rapid field detection of novel coronavirus (2019-nCoV), influenza virus, mycoplasma pneumoniae and chlamydia pneumoniae, can break through the limitation of the existing detection technology on personnel/places, are short in detection time and simple to operate, can be used in places such as community health service centers, primary hospitals, airports, customs and families, and can realize rapid differential diagnosis of suspected patients of the novel coronavirus (2019-nCoV) and field screening of close contact people.
The foregoing detailed description of the preferred embodiments of the invention has been presented. It should be understood that numerous modifications and variations can be devised by those skilled in the art in light of the present teachings without departing from the inventive concepts. Therefore, the technical solutions available to those skilled in the art through logic analysis, reasoning and limited experiments based on the concepts of the present invention are all within the scope of protection defined by the claims.
Claims (10)
1. A novel coronavirus differential diagnosis test strip is characterized by comprising a bottom plate with a strip-shaped structure, wherein a sample pad, a marker pad, a nitrocellulose membrane and absorbent paper are sequentially arranged on the upper surface of the bottom plate along the longitudinal direction of the bottom plate; and the adjacent ends of the sample pad, the marker pad, the nitrocellulose membrane and the absorbent paper are in lap joint; the marker pad is coated with a novel coronavirus monoclonal antibody or/and a polyclonal antibody and a rabbit IgG antibody which are respectively marked by markers; a detection area is formed on one side of the upper surface of the nitrocellulose membrane, a novel coronavirus detection line is arranged in the detection area, and the novel coronavirus detection line is coated with a novel coronavirus monoclonal antibody or/and a polyclonal antibody.
2. The novel coronavirus differential diagnosis test strip of claim 1, which is characterized in that: a quality control area is formed on the other side of the upper surface of the nitrocellulose membrane; the quality control area is provided with a quality control line coated with goat anti-rabbit IgG antibody.
3. The novel coronavirus differential diagnosis test strip of claim 1, which is characterized in that: the marker pad is further coated with an influenza virus monoclonal antibody or/and polyclonal antibody marked by a marker, a mycoplasma pneumoniae monoclonal antibody or/and polyclonal antibody marked by a marker and a chlamydia pneumoniae monoclonal antibody or/and polyclonal antibody marked by a marker; the detection area is also provided with an influenza virus detection line, a mycoplasma pneumoniae detection line and a chlamydia pneumoniae detection line; the influenza virus detection line is coated with influenza virus monoclonal antibodies or/and polyclonal antibodies, the mycoplasma pneumoniae detection line is coated with mycoplasma pneumoniae monoclonal antibodies or/and polyclonal antibodies, and the chlamydia pneumoniae detection line is coated with chlamydia pneumoniae monoclonal antibodies or/and polyclonal antibodies.
4. The novel coronavirus differential diagnosis test strip of claim 3, which is characterized in that: the novel coronavirus detection line is coated with a novel coronavirus monoclonal antibody, the influenza virus detection line is coated with an influenza virus monoclonal antibody, the mycoplasma pneumoniae detection line is coated with a mycoplasma pneumoniae monoclonal antibody, and the chlamydia pneumoniae detection line is coated with a chlamydia pneumoniae monoclonal antibody.
5. The novel coronavirus differential diagnosis test strip of claim 2, which is characterized in that: the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are mutually arranged in parallel and are sequentially arranged from left to right.
6. The novel coronavirus differential diagnosis test strip of claim 5, which is characterized in that: the intervals between the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are arranged in an equal way; the lengths of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are arranged in an equal way; the widths of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line are arranged in an equal way.
7. The novel coronavirus differential diagnosis test strip of claim 2, which is characterized in that: the interval between the adjacent two of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line is 1.0mm to 3.0 mm; the length of the novel coronavirus detection line, the influenza virus detection line, the mycoplasma pneumoniae detection line, the chlamydia pneumoniae detection line and the quality control line is 2.0mm to 5.0mm, and the width of the novel coronavirus detection line is 0.5mm to 1.0 mm.
8. The novel coronavirus differential diagnosis test strip of claim 1, which is characterized in that: the nitrocellulose membrane has a length of 2cm to 3cm and a width of 2.0mm to 5.0 mm.
9. The novel coronavirus differential diagnosis test strip of claim 1, which is characterized in that: the sample pad is lapped on the marker pad, and the length of the lapping part is 1.0-3.0 mm; the marker pad is lapped on the nitrocellulose membrane, the length of a lapping part is 1.0-3.0 mm, the absorbent paper is lapped on the nitrocellulose membrane, and the lapping length is 1.0-3.0 mm.
10. A novel coronavirus differential diagnosis test card, which comprises the novel coronavirus differential diagnosis test strip of any one of claims 1 to 9; still including the last card shell and the lower card shell of dismantling the connection, be fixed with on the card shell down the test paper strip, go up card shell correspondence has the position of sample pad is provided with the application of sample hole and corresponds the nitrocellulose membrane position is provided with the detection window.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202020169935.3U CN210894377U (en) | 2020-02-14 | 2020-02-14 | Novel coronavirus differential diagnosis test paper strip and detection card |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202020169935.3U CN210894377U (en) | 2020-02-14 | 2020-02-14 | Novel coronavirus differential diagnosis test paper strip and detection card |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN210894377U true CN210894377U (en) | 2020-06-30 |
Family
ID=71321536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202020169935.3U Active CN210894377U (en) | 2020-02-14 | 2020-02-14 | Novel coronavirus differential diagnosis test paper strip and detection card |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN210894377U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111879933A (en) * | 2020-07-30 | 2020-11-03 | 广州德成生物科技有限公司 | Immunochromatography test paper for detecting novel coronavirus |
-
2020
- 2020-02-14 CN CN202020169935.3U patent/CN210894377U/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111879933A (en) * | 2020-07-30 | 2020-11-03 | 广州德成生物科技有限公司 | Immunochromatography test paper for detecting novel coronavirus |
| CN111879933B (en) * | 2020-07-30 | 2023-10-03 | 广州德成生物科技有限公司 | Immunochromatography test paper for detecting novel coronavirus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Iglὁi et al. | Clinical evaluation of Roche SD Biosensor rapid antigen test for SARS-CoV-2 in municipal health service testing site, the Netherlands | |
| Frazee et al. | Accuracy and discomfort of different types of intranasal specimen collection methods for molecular influenza testing in emergency department patients | |
| Njama-Meya et al. | Treatment of malaria restricted to laboratory-confirmed cases: a prospective cohort study in Ugandan children | |
| Sundell et al. | PCR detection of respiratory pathogens in asymptomatic and symptomatic adults | |
| Arwady et al. | Middle East respiratory syndrome coronavirus transmission in extended family, Saudi Arabia, 2014 | |
| Chansamouth et al. | The aetiologies and impact of fever in pregnant inpatients in Vientiane, Laos | |
| Asif et al. | Diagnosis of COVID-19, vitality of emerging technologies and preventive measures | |
| El-Zein et al. | Human papillomavirus infection and transmission among couples through heterosexual activity (HITCH) cohort study: protocol describing design, methods, and research goals | |
| Rahman et al. | Performance of Binax NOW Flu A and B and direct fluorescent assay in comparison with a composite of viral culture or reverse transcription polymerase chain reaction for detection of influenza infection during the 2006 to 2007 season | |
| Borrero H et al. | Acute respiratory tract infections among a birth cohort of children from Cali, Colombia, who were studied through 17 months of age | |
| Cerigo et al. | Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec | |
| Kashiwagi et al. | Immunochromatographic test for the detection of SARS-CoV-2 in saliva | |
| Leonardi et al. | Evaluation of respiratory syncytial virus (RSV) direct antigen detection assays for use in point-of-care testing | |
| Pascoe et al. | Field evaluation of diagnostic accuracy of an oral fluid rapid test for HIV, tested at point-of-service sites in rural Zimbabwe | |
| Devillier et al. | Biomedical detection dogs for the identification of SARS-CoV-2 infections from axillary sweat and breath samples | |
| CN210894377U (en) | Novel coronavirus differential diagnosis test paper strip and detection card | |
| Pandey et al. | Comparison of the rapid antigen testing method with RT-qPCR for the diagnosis of COVID-19 | |
| Leixner et al. | Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting | |
| Fitoussi et al. | Analytical performance of the point-of-care BIOSYNEX COVID-19 Ag BSS for the detection of SARS‐CoV‐2 nucleocapsid protein in nasopharyngeal swabs: a prospective field evaluation during the COVID-19 third wave in France | |
| Van Wagoner et al. | Herpes diagnostic tests and their use | |
| Cruz et al. | Performance characteristics of a rapid immunochromatographic assay for detection of influenza virus in children during the 2003 to 2004 influenza season | |
| Rodrigo et al. | Clinical and laboratory diagnosis of influenza | |
| Rahman et al. | Performance of Directigen flu A+ B enzyme immunoassay and direct fluorescent assay for detection of influenza infection during the 2004–2005 season | |
| Palikša et al. | Saliva testing is a robust non-invasive method for SARS-CoV-2 RNA detection | |
| Kaur et al. | Antitrichomonas IgG, IgM, IgA, and IgG subclass responses in human intravaginal trichomoniasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |